SXTC

Peers: LLY NVS JNJ AMGN AZN MRK ABBV PFE BMY GILD

Index	-	P/E	-	EPS (ttm)	-2.17	Insider Own	35.32%	Shs Outstand	-	Perf Week	-5.95%
Market Cap	161.28M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	75.04M	Perf Month	-26.84%
Enterprise Value	144.13M	PEG	-	EPS next Q	-	Inst Own	0.07%	Short Float	0.19%	Perf Quarter	-14.43%
Income	-3.30M	P/S	92.69	EPS this Y	-	Inst Trans	44.62%	Short Ratio	0.48	Perf Half Y	-35.65%
Sales	1.74M	P/B	1.24	EPS next Y	-	ROA	-14.75%	Short Interest	0.15M	Perf YTD	-65.80%
Book/sh	1.12	P/C	8.90	EPS next 5Y	-	ROE	-22.50%	52W High	7.84 -82.27%	Perf Year	-72.53%
Cash/sh	0.16	P/FCF	-	EPS past 3/5Y	95.28% 79.65%	ROIC	-21.11%	52W Low	0.95 46.32%	Perf 3Y	-99.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.54% -19.54%	Gross Margin	21.11%	Volatility	4.78% 9.87%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	82.83	EPS Y/Y TTM	98.34%	Oper. Margin	-96.18%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.35	Sales Y/Y TTM	-9.73%	Profit Margin	-189.77%	RSI (14)	34.81	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	3.54	EPS Q/Q	-	SMA20	-12.60%	Beta	1.47	Target Price	-
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-13.39%	Rel Volume	0.01	Prev Close	1.42
Employees	75	LT Debt/Eq	0.01	Earnings	-	SMA200	-38.84%	Avg Volume	304.58K	Price	1.39
IPO	Jan 04, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	3,718	Change	-2.11%

Mar-17-25 08:30AM	China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency (GlobeNewswire) -7.09%
Feb-21-25 12:35PM	China SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -8.70%
Oct-07-24 04:15PM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire) -10.28%
Oct-26-23 04:05PM	China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule (GlobeNewswire) +6.75%
Oct-04-23 08:30AM	China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split (GlobeNewswire)
06:03AM	Loading…
Aug-02-23 06:03AM	China SXT Pharmaceuticals Full Year 2023 Earnings: US$0.89 loss per share (vs US$5.52 loss in FY 2022) (Simply Wall St.)
May-10-23 08:00AM	China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule (GlobeNewswire) +6.05%
Mar-29-23 09:43AM	Insiders who placed huge bets on China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) earlier this year would be disappointed with the 12% drop (Simply Wall St.)
Nov-07-22 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire)
May-18-22 12:30PM	China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split (GlobeNewswire) -27.93%
Mar-14-22 10:33PM	China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million (GlobeNewswire) -9.81%
Jan-20-22 12:30PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). (ACCESSWIRE)
10:45AM	China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment (GlobeNewswire)
Jan-18-22 07:46AM	China SXT Pharmaceuticals Shares Plunge On $3.5M Equity Raise Issued At Steep Discount (Benzinga) -58.77%
06:47AM	China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares (GlobeNewswire)
05:43PM	Loading…
Jan-14-22 05:43PM	China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares (GlobeNewswire)
02:00PM	China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin (PR Newswire)
Dec-16-21 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (PR Newswire)
Oct-18-21 08:00AM	China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection (PR Newswire) +9.59%
Feb-19-21 08:00AM	China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split (PR Newswire) -23.04%
Nov-26-20 08:16PM	Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy? (Insider Monkey)
Sep-09-20 09:00AM	NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement (PR Newswire) +6.93%
May-29-20 03:08PM	Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC) (Insider Monkey) -5.61%
Mar-16-20 09:00AM	China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government (PR Newswire) -11.45%
Jan-28-20 09:35AM	How Does China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Compare To Its Industry, After Its Big Share Price Gain? (Simply Wall St.) -13.50%
Jan-24-20 02:23PM	China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production (Business Wire)
Jan-16-20 08:00AM	China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory (PR Newswire) +6.98%
Jan-03-20 10:30AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (PR Newswire)
Dec-04-19 07:10AM	What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked? (Simply Wall St.)
Nov-14-19 11:30AM	Should You Worry About China SXT Pharmaceuticals, Inc.s (NASDAQ:SXTC) ROCE? (Simply Wall St.)
07:00AM	Loading…
Sep-11-19 07:00AM	China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques (PR Newswire)
Aug-19-19 08:00AM	China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019 (PR Newswire)
Aug-12-19 08:00AM	China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate (PR Newswire) +20.26%
Jul-03-19 08:00AM	China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production (PR Newswire)
May-22-19 11:20AM	China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province (PR Newswire)
Apr-17-19 09:00AM	China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing (PR Newswire) -11.72%
Apr-02-19 06:30AM	China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification (PR Newswire)
Mar-28-19 06:30AM	China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018 (PR Newswire)
Jan-30-19 02:25PM	4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19) (ACCESSWIRE) +43.81%
Jan-04-19 07:30AM	China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering (PR Newswire)

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

China SXT Pharmaceuticals Inc

Upgrade your FINVIZ experience